Dataset Information

Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma.

ABSTRACT: Pseudoprogression (PsP) is a diagnostic clinical dilemma in cancer. In this study, we retrospectively analyse glioblastoma patients, and using their dynamic susceptibility contrast and dynamic contrast-enhanced perfusion MRI images we build a classifier using radiomic features obtained from both Ktrans and rCBV maps coupled with support vector machines. We achieve an accuracy of 90.82% (area under the curve (AUC) = 89.10%, sensitivity = 91.36%, 67 specificity = 88.24%, p = 0.017) in differentiating between pseudoprogression (PsP) and progressive disease (PD). The diagnostic performances of the models built using radiomic features from Ktrans and rCBV separately were equally high (Ktrans: AUC = 94%, 69 p = 0.012; rCBV: AUC = 89.8%, p = 0.004). Thus, this MR perfusion-based radiomic model demonstrates high accuracy, sensitivity and specificity in discriminating PsP from PD, thus provides a reliable alternative for noninvasive identification of PsP versus PD at the time of clinical/radiologic question. This study also illustrates the successful application of radiomic analysis as an advanced processing step on different MR perfusion maps.

SUBMITTER: Elshafeey N

PROVIDER: S-EPMC6639324 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma.

Elshafeey Nabil N Kotrotsou Aikaterini A Hassan Ahmed A Elshafei Nancy N Hassan Islam I Ahmed Sara S Abrol Srishti S Agarwal Anand A El Salek Kamel K Bergamaschi Samuel S Acharya Jay J Moron Fanny E FE Law Meng M Fuller Gregory N GN Huse Jason T JT Zinn Pascal O PO Colen Rivka R RR

Nature communications 20190718 1

Pseudoprogression (PsP) is a diagnostic clinical dilemma in cancer. In this study, we retrospectively analyse glioblastoma patients, and using their dynamic susceptibility contrast and dynamic contrast-enhanced perfusion MRI images we build a classifier using radiomic features obtained from both Ktrans and rCBV maps coupled with support vector machines. We achieve an accuracy of 90.82% (area under the curve (AUC) = 89.10%, sensitivity = 91.36%, 67 specificity = 88.24%, p = 0.017) in differentiat ...[more]

PMID: 31320621

Similar Datasets

Project description:BackgroundPseudoprogression (PsPD) is a major diagnostic challenge in the follow-up of patients with glioblastoma (GB) after chemoradiotherapy (CRT). Conventional imaging signs and parameters derived from diffusion and perfusion-MRI have yet to prove their reliability in clinical practice for an accurate differential diagnosis. Here, we tested these parameters and combined them with radiomic features (RFs), clinical data, and MGMT promoter methylation status using machine- and deep-learning (DL) models to distinguish PsPD from Progressive disease.MethodsIn a single-center analysis, 105 patients with GB who developed a suspected imaging PsPD in the first 7 months after standard CRT were identified retrospectively. Imaging data included standard MRI anatomical sequences, apparent diffusion coefficient (ADC), and normalized relative cerebral blood volume (nrCBV) maps. Median values (ADC, nrCBV) and RFs (all sequences) were calculated from DL-based tumor segmentations. Generalized linear models with LASSO feature-selection and DL models were built integrating clinical data, MGMT methylation status, median ADC and nrCBV values and RFs.ResultsA model based on clinical data and MGMT methylation status yielded an areas under the receiver operating characteristic curve (AUC) = 0.69 (95% CI 0.55-0.83) for detecting PsPD, and the addition of median ADC and nrCBV values resulted in a nonsignificant increase in performance (AUC = 0.71, 95% CI 0.57-0.85, P = .416). Combining clinical/MGMT information with RFs derived from ADC, nrCBV, and from all available sequences both resulted in significantly (both P < .005) lower model performances, with AUC = 0.52 (0.38-0.66) and AUC = 0.54 (0.40-0.68), respectively. DL imaging models resulted in AUCs ≤ 0.56.ConclusionCurrently available imaging biomarkers could not reliably differentiate PsPD from true tumor progression in patients with glioblastoma; larger collaborative efforts are needed to build more reliable models.

Project description:BackgroundLymph node metastasis is an important factor affecting the treatment and prognosis of patients with cervical cancer. However, the comparison of different algorithms and features to predict lymph node metastasis is not well understood. This study aimed to construct a non-invasive model for predicting lymph node metastasis in patients with cervical cancer based on clinical features combined with the radiomic features of magnetic resonance imaging (MRI) images.MethodsA total of 180 cervical cancer patients were divided into the training set (n = 126) and testing set (n = 54). In this cross-sectional study, radiomic features of MRI images and clinical features of patients were collected. The least absolute shrinkage and selection operator (LASSO) regression was used to filter the features. Seven machine learning methods, including eXtreme Gradient Boosting (XGBoost), Logistic Regression, Multinomial Naive Bayes (MNB), Support Vector Machine (SVM), Decision Tree, Random Forest, and Gradient Boosting Decision Tree (GBDT) are used to build the models. Receiver operating characteristics (ROC) curve and area under the curve (AUC), accuracy, sensitivity, and specificity were calculated to assess the performance of the models.ResultsOf these 180 patients, 49 (27.22%) patients had lymph node metastases. Five of the 122 radiomic features and 3 clinical features were used to build predictive models. Compared with other models, the MNB model was the most robust, with its AUC, specificity, and accuracy on the testing set of 0.745 (95%CI: 0.740-0.750), 0.900 (95%CI: 0.807-0.993), and 0.778 (95%CI: 0.667-0.889), respectively. Furthermore, the AUCs of the MNB models with clinical features only, radiomic features only, and combined features were 0.698 (95%CI: 0.692-0.704), 0.632 (95%CI: 0.627-0.637), and 0.745 (95%CI: 0.740-0.750), respectively.ConclusionThe MNB model, which combines the radiomic features of MRI images with the clinical features of the patient, can be used as a non-invasive tool for the preoperative assessment of lymph node metastasis.

Dataset Information

Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma.

Publications

Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets